Adult Attention Deficit Hyperactivity Disorder Clinical Trial
Official title:
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder - a Randomized Controlled Trial
In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis. Inclusion criteria are: male, female or non-binary, age 18-65, diagnosis of ADHD, elevated levels of ADHD symptoms (score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1), stable treatment for at least 30 days at time of inclusion, sufficient German skills, and consent to participation. Exclusion criteria are: Diagnosis of any other severe psychiatric disorder and plans to change treatment in the upcoming three months. Patients will be randomized and allocated to either an intervention group, receiving access to attexis in addition to TAU, or a control group, receiving access to TAU only. Primary endpoint will be self-rated ADHD symptomatology, assessed via the ASRS v1.1, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, self-esteem, work and social functioning, and health-related quality of life.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000501 -
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
|
Phase 4 | |
| Completed |
NCT03721588 -
Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
|
||
| Completed |
NCT03324581 -
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
|
Phase 2 | |
| Completed |
NCT02160262 -
Open-label Safety Study in Adults With ADHD
|
Phase 3 | |
| Completed |
NCT02276209 -
Dasotraline Adult ADHD Study
|
Phase 3 | |
| Completed |
NCT01692782 -
Adult Attention Deficit Hyperactivity Disorder
|
Phase 2 | |
| Completed |
NCT01798381 -
Essential Fatty Acids in Adult ADHD
|
Phase 3 | |
| Completed |
NCT00553319 -
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
|
Phase 2/Phase 3 |